The UAB Comprehensive Cancer Center Senior Leadership is comprised of seven individuals supported by the CCSG: Director - Edward E. Partridge, IVI.D. Deputy Director- Boris C. Pasche, M.D., Ph.D. Associate Director for Basic Research - Etty (Tika) Benveniste, Ph.D. Associate Director for Translational Research - Mary-Ann Bjornsti, Ph.D. Associate Director for Clinical Research - Albert F. LoBuglio, M.D. Associate Director for Prevention and Control - Wendy Demark-Wahnefried, Ph.D. Associate Director for Administration - Michael J. Bertram, Ph.D. There have been major changes in Senior Leadership since the last competitive renewal. Following a national search for a new Director, Dr. Edward E. Partridge was named Director in July of 2007. Dr. Partridge has a longstanding history in the UAB Comprehensive Cancer Center (UAB CCC) and has played various leadership roles over the past two decades. His primary areas of expertise include clinical and cancer control research. Other new Senior Leaders include Dr. Boris C. Pasche as Deputy Director, replacing Dr. Kirby Bland, now Senior Advisor to the Director;Dr. Etty Benveniste as Associate Director for Basic Research, replacing Dr. Robert Diasio, now Director of the Mayo Comprehensive Cancer Center;Dr. Albert LoBuglio as Associate Director for Clinical Research, following Dr. Sam Beenken's departure;Dr. Mary-Ann Bjornsti to the newly created position of Associate Director for Translational Research;Dr. Wendy Demark-Wahnefried as Associate Director for Prevention and Control, replacing Dr. Partridge;and Dr. Michael Bertram as Associate Director for Administration.
Because of the investment of the National Cancer Institute in a Comprehensive Cancer Center, the center needs leadership that understands stewardship of public trust. The UAB CCC leadership's mission is to assure that the center fulfills the NCI goals of reducing morbidity and mortality from cancer;discovering the nature of cancer;understanding cancer biology;developing effective prevention, diagnosis, and therapy.; delivering medical advances to patients and their families;educating healthcare professionals and the public; and reaching out to underserved populations.
|Fauci, Janelle M; Sabbatino, Francesco; Wang, Yangyang et al. (2014) Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol 132:203-10|
|Carson, Tiffany L; Hardy, Claudia M; Greene, Eva et al. (2014) Considerations for bio-specimen collection among black women residing in the rural Deep South participating in a cancer prevention study. J Community Genet 5:257-63|
|Kim, Hyunki; Rigell, Christopher J; Zhai, Guihua et al. (2014) Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Mol Imaging Biol 16:85-94|
|Devine, D J; Rostas, J W; Metge, B J et al. (2014) Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-*/SMAD signaling. Oncogene 33:2620-8|
|Sonpavde, Guru; Willey, Christopher D; Sudarshan, Sunil (2014) Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. Expert Opin Investig Drugs 23:305-15|
|Saini, Reshu; Hoyt, Kenneth (2014) Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis. Imaging Med 6:41-52|
|Shim, Eun-Hee; Livi, Carolina B; Rakheja, Dinesh et al. (2014) L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov 4:1290-8|
|Gan, Yujun; Buckels, Ashiya; Liu, Ying et al. (2014) Human GH receptor-IGF-1 receptor interaction: implications for GH signaling. Mol Endocrinol 28:1841-54|
|Johnson, David H; Wilson, W William; DeLucas, Lawrence J (2014) Protein solubilization: a novel approach. J Chromatogr B Analyt Technol Biomed Life Sci 971:99-106|
|Ramos, Theresa N; Bullard, Daniel C; Barnum, Scott R (2014) ICAM-1: isoforms and phenotypes. J Immunol 192:4469-74|
Showing the most recent 10 out of 364 publications